Cloaked Therapeutics Development

Cloaked Therapeutics Development is a biopharmaceutical company focused on the development of the TumorSelect platform, a targeted drug delivery system for oncology. The technology utilizes "cloaked" prodrugs of cytotoxic agents, such as taxanes, which are encapsulated in nanoparticles that mimic low-density lipoprotein (LDL). Since tumor cells have a high demand for cholesterol and overexpress LDL receptors, the "pseudo LDL" particles are selectively internalized by the tumor, where the prodrug is converted into its active form. This approach aims to maximize therapeutic efficacy while significantly reducing the systemic toxicity typically associated with conventional chemotherapy. The company is currently in the pre-clinical stage, advancing programs for various solid tumors including melanoma, pancreatic cancer, and glioblastoma. Cloaked Therapeutics Development operates as a joint venture between Cloaked Therapeutics and Romulus Titan.